NX-1207
- Generic Name
- NX-1207
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- 9L8TV1O7E0
Overview
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Background
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Indication
Investigated for use/treatment in benign prostatic hyperplasia.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath